|
|
|
|||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
Institut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS-INSERM-ULP-Collège de France, BP163, 67404 Illkirch Cedex, C.U. de Strasbourg, France
*Author for correspondence (e-mail: chambon{at}igbmc.u-strasbg.fr)
Accepted March 8, 2001
We have engineered a mouse mutation that specifically deletes most of the RXR
N-terminal A/B region, which includes the activation function AF-1 and several phosphorylation sites. The homozygous mutants (RXR
af1o), as well as compound mutants that further lack RXRß and RXR
, are viable and display a subset of the abnormalities previously described in RXR
-null mutants. In contrast, RXR
af1o/RAR-/-(
, ß or
) compound mutants die in utero and exhibit a large array of malformations that nearly recapitulate the full spectrum of the defects that characterize the fetal vitamin A-deficiency (VAD) syndrome. Altogether, these observations indicate that the RXR
AF-1 region A/B is functionally important, although less so than the ligand-dependent activation function AF-2, for efficiently transducing the retinoid signal through RAR/RXR
heterodimers during embryonic development. Moreover, it has a unique role in retinoic acid-dependent involution of the interdigital mesenchyme. During early placentogenesis, both the AF-1 and AF-2 activities of RXR
, ß and
appear to be dispensable, suggesting that RXRs act as silent heterodimeric partners in this process. However, AF-2 of RXR
, but not AF-1, is required for differentiation of labyrinthine trophoblast cells, a late step in the formation of the placental barrier.
Key words: Nuclear receptor, Retinoic acid, Gene knockout, Transcriptional activity, Activation function, Placenta, Limb, Mouse
This article has been cited by other articles:
![]() |
P. Germain, P. Chambon, G. Eichele, R. M. Evans, M. A. Lazar, M. Leid, A. R. De Lera, R. Lotan, D. J. Mangelsdorf, and H. Gronemeyer International Union of Pharmacology. LXIII. Retinoid X Receptors Pharmacol. Rev., December 1, 2006; 58(4): 760 - 772. [Abstract] [Full Text] [PDF] |
||||
![]() |
Genetically Modified Animals in Endocrinology Endocr. Rev., December 1, 2005; 26(7): 985 - 993. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Chen, S. Beaven, and P. Tontonoz Identification and characterization of two alternatively spliced transcript variants of human liver X receptor alpha J. Lipid Res., December 1, 2005; 46(12): 2570 - 2579. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Nakanishi, J.-i. Nishikawa, Y. Hiromori, H. Yokoyama, M. Koyanagi, S. Takasuga, J.-i. Ishizaki, M. Watanabe, S.-i. Isa, N. Utoguchi, et al. Trialkyltin Compounds Bind Retinoid X Receptor to Alter Human Placental Endocrine Functions Mol. Endocrinol., October 1, 2005; 19(10): 2502 - 2516. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Chambon The Nuclear Receptor Superfamily: A Personal Retrospect on the First Two Decades Mol. Endocrinol., June 1, 2005; 19(6): 1418 - 1428. [Full Text] [PDF] |
||||
![]() |
M. Mori, D. Metzger, S. Picaud, C. Hindelang, M. Simonutti, J. Sahel, P. Chambon, and M. Mark Retinal Dystrophy Resulting from Ablation of RXR{alpha} in the Mouse Retinal Pigment Epithelium Am. J. Pathol., February 1, 2004; 164(2): 701 - 710. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Dupe, N. Matt, J.-M. Garnier, P. Chambon, M. Mark, and N. B. Ghyselinck A newborn lethal defect due to inactivation of retinaldehyde dehydrogenase type 3 is prevented by maternal retinoic acid treatment PNAS, November 25, 2003; 100(24): 14036 - 14041. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Matt, N. B. Ghyselinck, O. Wendling, P. Chambon, and M. Mark Retinoic acid-induced developmental defects are mediated by RAR{beta}/RXR heterodimers in the pharyngeal endoderm Development, May 15, 2003; 130(10): 2083 - 2093. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Cherbas, X. Hu, I. Zhimulev, E. Belyaeva, and P. Cherbas EcR isoforms in Drosophila: testing tissue-specific requirements by targeted blockade and rescue Development, March 2, 2003; 130(2): 271 - 284. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Desclozeaux, I. N. Krylova, F. Horn, R. J. Fletterick, and H. A. Ingraham Phosphorylation and Intramolecular Stabilization of the Ligand Binding Domain in the Nuclear Receptor Steroidogenic Factor 1 Mol. Cell. Biol., October 15, 2002; 22(20): 7193 - 7203. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Bastien, S. Adam-Stitah, J.-L. Plassat, P. Chambon, and C. Rochette-Egly The Phosphorylation Site Located in the A Region of Retinoic X Receptor alpha Is Required for the Antiproliferative Effect of Retinoic Acid (RA) and the Activation of RA Target Genes in F9 Cells J. Biol. Chem., August 2, 2002; 277(32): 28683 - 28689. [Abstract] [Full Text] [PDF] |
||||